| Identification | Back Directory | [Name]
Isobutyl-deoxynyboquinone
(IB-DNQ) | [CAS]
1430798-22-3 | [Synonyms]
IB-DNQ
Isobutyl-deoxynyboquinone
(IB-DNQ) | [Molecular Formula]
C18H18N2O4 | [MDL Number]
MFCD34469371 | [MOL File]
1430798-22-3.mol | [Molecular Weight]
326.35 |
| Chemical Properties | Back Directory | [Boiling point ]
589.9±50.0 °C(Predicted) | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
7.14±0.60(Predicted) | [color ]
Brown to red |
| Hazard Information | Back Directory | [Uses]
Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1). Isobutyl-deoxynyboquinone can be used for the research of anticancer[1]. | [in vivo]
Isobutyl-deoxynyboquinone (0.5~2 mg/kg; i.v.; 20 hours) achieves average peak plasma concentration levels. Isobutyl-deoxynyboquinone (1 mg/kg; p.o.; 4 hours) achieves peak plasma concentrations[1]. | Animal Model: | Cats | | Dosage: | 0.5~2 mg/kg (Pharmacokinetic Analysis) | | Administration: | I.v. | | Result: | Achieved average peak plasma concentration levels.
|
| Animal Model: | Cats | | Dosage: | 1 mg/kg (Pharmacokinetic Analysis) | | Administration: | P.o. | | Result: | Achieved peak plasma concentration.
|
| [References]
[1] Lundberg AP, et al. Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species. Invest New Drugs. 2017;35(2):134-144. DOI:10.1007/s10637-016-0414-z |
|
|